At the Beacon Angels meeting on Tuesday, March 12, 2024, we entertained new funding presentations as follows:

• Glycologix, developing, GLX-100, a biopolymer medical device for the novel treatment of the underserved millions with interstitial cystitis/bladder pain syndrome.
• Agile Devices, which has developed the FDA-cleared Angler® Steerable and Deflectable Microcatheter, a novel device with a fully intraoperative active tip control for neurovascular, coronary and peripheral use cases; and
• AI Lean, which outsources the lien-to-auction process for self-storage owners, automating collections, liens and auctions management.

Members reported on pending funding rounds, by Series number.

• 112B Theromics, developing tumor-targeting therapies ($30K held);
• 116B Realplay, providing video highlights for youth sports ($40K invested)
• 122 GelMEDIX improving drug delivery for the eye ($190k invested, of which $76K held in escrow); and
• 126 myBiometry developing an advanced early-warning system for asthma attacks ($35K held awaiting company docs).

Members reported on companies in due diligence:

• Surgicure Technologies, developing a device to improve intubation quality and safety.

Members reported on pending funding rounds, by Series number.

• 112B Theromics, developing tumor-targeting therapies;
• 116B Realplay, providing video highlights for youth sports;
• 122 GelMEDIX improving drug delivery for the eye; and
• 126 myBiometry developing an advanced early-warning system for asthma attacks ($35K held awaiting company docs).